Ventyx Biosciences (VTYX) to Release Earnings on Tuesday

Ventyx Biosciences (NASDAQ:VTYX) will likely be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect Ventyx Biosciences to post earnings of ($0.54) per share for the quarter.

Ventyx Biosciences Stock Down 3.0 %

Ventyx Biosciences stock opened at $1.61 on Friday. The business has a 50-day simple moving average of $2.04 and a two-hundred day simple moving average of $2.16. The company has a market cap of $113.84 million, a P/E ratio of -0.68 and a beta of 0.52. Ventyx Biosciences has a 52-week low of $1.57 and a 52-week high of $11.48.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Oppenheimer reiterated an “outperform” rating and set a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reissued a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Insider Transactions at Ventyx Biosciences

In other news, insider John Nuss sold 13,161 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the sale, the insider now directly owns 485,701 shares of the company’s stock, valued at $1,097,684.26. This represents a 2.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Raju Mohan acquired 261,752 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were purchased at an average cost of $2.01 per share, for a total transaction of $526,121.52. Following the completion of the acquisition, the chief executive officer now directly owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This represents a 13.68 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 18.18% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.